News

The expansion is expected to help the pharmaceutical company in creating about 100 new jobs at its Dortmund site. Boehringer Ingelheim member of the Board of Managing Directors

Dupilumab is an investigational therapy that blocks IL-4 and IL-13 signaling. The results showed that dupilumab met all primary and secondary endpoints in these patients who did not

The trial is designed to assess the efficacy of DanDrit’s vaccine MelCancerVac (MCV) in stage IV CRC patients rendered disease free after the completion of standard treatments in

MAA for nivolumab is the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. Bristol-Myers Squibb senior vice-president and head of Oncology Development

VVA results from the decrease in naturally occurring estrogen during menopause, resulting in thinning of the vaginal lining and an increase in vaginal pH levels. The Phase III

In May 2014, the companies have agreed on the development of MGD010, and the four new research programs are in addition to that product. Each of the four

Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia; efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support

"With ImmunoClin’s track record in assisting biotech, pharma and food companies as well as public institutions in pharmaceutical and nutraceutical development projects, we are excited to initiate this

Based on a planned interim analysis of the co-primary endpoint, the objective response rate (ORR) was 32% (95% CI = 24, 41) in the Opdivo arm (n=120) and